AEGON ASSET MANAGEMENT UK Plc Grows Stock Holdings in Veeva Systems Inc. $VEEV

AEGON ASSET MANAGEMENT UK Plc increased its stake in shares of Veeva Systems Inc. (NYSE:VEEV) by 5.7% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 119,849 shares of the technology company’s stock after purchasing an additional 6,422 shares during the period. AEGON ASSET MANAGEMENT UK Plc owned approximately 0.07% of Veeva Systems worth $34,489,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in VEEV. GAMMA Investing LLC raised its holdings in shares of Veeva Systems by 13.8% during the first quarter. GAMMA Investing LLC now owns 1,823 shares of the technology company’s stock valued at $422,000 after purchasing an additional 221 shares during the last quarter. Janney Montgomery Scott LLC bought a new stake in Veeva Systems during the first quarter valued at approximately $5,876,000. Sowell Financial Services LLC bought a new stake in Veeva Systems during the first quarter valued at approximately $274,000. QRG Capital Management Inc. grew its position in Veeva Systems by 6.1% during the first quarter. QRG Capital Management Inc. now owns 11,036 shares of the technology company’s stock valued at $2,556,000 after buying an additional 634 shares during the period. Finally, Schaper Benz & Wise Investment Counsel Inc. WI grew its position in Veeva Systems by 7.9% during the first quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 6,387 shares of the technology company’s stock valued at $1,479,000 after buying an additional 466 shares during the period. 88.20% of the stock is owned by hedge funds and other institutional investors.

Veeva Systems Price Performance

VEEV opened at $287.81 on Wednesday. The firm has a market cap of $47.17 billion, a P/E ratio of 59.10, a PEG ratio of 2.21 and a beta of 0.98. Veeva Systems Inc. has a 1-year low of $201.54 and a 1-year high of $310.50. The company has a 50 day simple moving average of $283.06 and a two-hundred day simple moving average of $265.77.

Veeva Systems (NYSE:VEEV) last posted its quarterly earnings results on Wednesday, August 27th. The technology company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.90 by ($0.64). Veeva Systems had a return on equity of 13.72% and a net margin of 27.29%.The firm had revenue of $789.08 million during the quarter, compared to the consensus estimate of $768.49 million. During the same quarter in the previous year, the company earned $1.62 earnings per share. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. Equities analysts anticipate that Veeva Systems Inc. will post 4.35 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Thomas D. Schwenger sold 3,350 shares of the company’s stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $300.04, for a total transaction of $1,005,134.00. Following the completion of the transaction, the insider owned 23,773 shares in the company, valued at approximately $7,132,850.92. This represents a 12.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Eleni Nitsa Zuppas sold 6,000 shares of the company’s stock in a transaction on Tuesday, October 7th. The stock was sold at an average price of $306.62, for a total transaction of $1,839,720.00. Following the transaction, the insider owned 25,325 shares of the company’s stock, valued at approximately $7,765,151.50. This represents a 19.15% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 24,665 shares of company stock worth $7,438,000. 10.30% of the stock is owned by insiders.

Analyst Ratings Changes

VEEV has been the subject of several recent research reports. Citigroup boosted their target price on shares of Veeva Systems from $329.00 to $349.00 and gave the company a “buy” rating in a research report on Thursday, August 28th. JPMorgan Chase & Co. upgraded shares of Veeva Systems from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $290.00 to $330.00 in a research report on Monday, September 8th. Truist Financial boosted their target price on shares of Veeva Systems from $268.00 to $275.00 and gave the company a “hold” rating in a research report on Thursday, August 28th. Evercore ISI boosted their target price on shares of Veeva Systems from $285.00 to $295.00 and gave the company an “in-line” rating in a research report on Thursday, August 28th. Finally, TD Cowen upgraded shares of Veeva Systems from a “hold” rating to a “buy” rating and boosted their target price for the company from $297.00 to $380.00 in a research report on Tuesday, October 7th. Sixteen research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $307.58.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.